This post was originally published on this site African American men recently diagnosed with prostate cancer are being recruited across the U.S. for the largest-ever prostate cancer study in this ethnic group. The study is a joint effort by prostate cancer researchers and experts from around the country and will seek to find out why African…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Activities Underway to Mark Ovarian Cancer Awareness Month
This post was originally published on this site Efforts including financial assistance, fundraising and education are underway to mark Ovarian Cancer Awareness Month. The annual September observance includes specialty lender Fifth Season Financial, which seeks to ease the financial burden of treatment of ovarian cancer, prostate cancer and other advanced-stage disorders. The lender’s Funds for Living…
Cancer Patients Around the World to Receive Henry Schein ‘Comfort Kits’
This post was originally published on this site Henry Schein, a foundation devoted to promoting dental and medical health, has produced more than 27,000 comfort kits for people fighting cancer in the U.S. The kits, which are meant to make patients feel at home while receiving care away from home, were assembled by more than 2,100 Team…
FDA Grants Orphan Drug Status to BioXcel’s BXCL701 as Potential AML Treatment
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BXCL701, one of BioXcel Therapeutics’ lead immunotherapies for the treatment of acute myeloid leukemia (AML). Orphan drug status is given to investigative treatments for rare diseases, defined in the U.S. as disorders that affect…
Cancer by the Numbers
This post was originally published on this site 1: Number of times a doctor told me, “Best-case scenario, you’ll be stuck with a ‘frankenboob.’ ” 0: Odds a doctor gave me that I’d be able to get chemo in time to save my life. 3: Months a doctor predicted I’d live. 10: Age of my daughter when…
Biosimilar ABP 798 Shows Similar Safety and Efficacy to Rituxan in Phase 3 Trial for Non-Hodgkin’s Lymphoma
This post was originally published on this site ABP 798, a biosimilar to Rituxan (rituximab), is showing comparable efficacy results to its original product in a Phase 3 trial for non-Hodgkin’s lymphoma patients, the treatment’s co-developers, Amgen and Allergan, have announced. The therapy also has a similar safety and immunogenicity (i.e., whether the immune system reacts against…
Health Canada and European Commission OK Tecentriq-Chemo Combo for Aggressive Lung Cancer
This post was originally published on this site Health Canada and the European Commission have approved Tecentriq (atezolizumab) in combination with chemotherapy (carboplatin plus etoposide) as a first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC), an aggressive form of lung cancer. Tecentriq is an immune checkpoint inhibitor developed and marketed by Genentech, a Roche…
Nerlynx Granted FDA’s Orphan Drug Status for Treating Breast Cancer with Brain Metastases
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Puma Biotechnology’s Nerlynx (neratinib) for the treatment of HER2-positive breast cancer in women with brain metastases. Between 10 to 15% of people with metastatic breast cancer develop brain metastases. However, that number reaches up to 30% in women…
Provenge Extends Survival of mCRPC Patients By Up to 4 Years, Data Show
This post was originally published on this site Treatment with the immunotherapy Provenge (sipuleucel-T) in a real-world setting is showing similar safety and efficacy in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) as in clinical trials, a study shows. The observational registry study — called PROCEED (NCT01306890) — conducted at urology…
Assay Shows Potential in Predicting Ovarian Cancer Response to Chemotherapy
This post was originally published on this site A new assay that grows patients’ cancer tissue in the lab and tests for treatment sensitivity may be able to spot ovarian cancer patients likely to respond best to first-line chemotherapy, a study showed. The ex vivo 3D cell culture (EV3D) assay, developed by Kiyatec, may lead…
Keytruda Plus Standard Therapy Fails to Improve Outcomes in Multiple Myeloma
This post was originally published on this site The addition of Keytruda (pembrolizumab) to standard therapy — Revlimid (lenalidomide) or Pomalyst (pomalidomide) in combination with dexamethasone — failed to improve the clinical outcomes of patients with untreated or relapsed/refractory multiple myeloma, data from two Phase 3 trials show. Findings from the trials were published in…
Ampligen Combo Safe, Effective in Treating Recurrent Ovarian Cancer, Phase 1 Study Shows
This post was originally published on this site A combination of Hemispherx Biopharma‘s investigational treatment Ampligen (rintatolimod) with chemo-immunotherapy is safe and effective in treating women with recurrent ovarian cancer, according to the final report of a Phase 1 study. While chemotherapy and immunotherapies have shown promise in fighting ovarian cancers, their activity may be…